THAC launches its new crowdfunding campaign
Join us!
Following the two first successfull campaigns, THAC launches a new crowdfunding campaign in collaboration with Happy Capital!
NEWS FLOW July 2022- A new scientific publication was published by THAC, highlighing that our active substance is a promising therpay for diabetes xith data in rodents and in humans. THAC submitted a new patent which further protects its future product (Aurelie le Lay et al., Helyon, July 2022)
“ALF-5755, coming from a major discovery in the
laboratories of INSERM, is a unique First-in-Class drug
candidate which could revolutionize T2DM patient’s management.
Its mechanism of action targets the root cause of the disease: appearance of insulin resistance during aging and depending of the life style More than an exceptional human experience,
we live in very exciting times as THAC is successfully speeding up
its clinical development and growth, with tremendous innovation
for the benefit of patients – the commitment of one life”.
Pr. Christian Bréchot, Chairman
The mission of THAC is to develop a First-In-Class drug candidate to address Type 2 Diabetes Mellitus (T2DM) and severe complications
THAC aims to change the way patient care and healthy aging are addressed by primarily focusing on Type 2 Diabetes Mellitus (T2DM) and its severe complications, with the potential to further address other age-related diseases.
THAC develops a range of first-in-class drug candidates to address insulin resistance, the root cause of T2DM, by acting on gut microbiota for better patient care and disease management.
THAC drug candidates, potential game changers for the treatment of Type 2 diabetes mellitus (T2DM)
THAC envisions that by acting on gut microbiota and fighting insulin resistance, the root cause of T2DM with its drug candidates, a major breakthrough could be achieved for the treatment of T2DM and the prevention of severe related complications such as diabetic neuropathy (e.g. diabetic foot wounds, amputations).
ALF-5755, the active ingredient of THAC drug candidates, is a first-in-class, first-in-man, GMP-produced recombinant bio-protein (17kDA) with a unique and innovative mechanism of action.
THAC drug candidate’ local activity on the microbiota is complementary to its systemic mechanism of action on other extracellular matrixes.
hgfdds
T2DM is the first worldwide non-infectious pandemics with still huge unmet medical needs
Type 2 Mellitus Diabetes (T2DM) is a still major unmet medical need claimed by the World Health Organization (WHO), American and European Diabetes Associations and other influential academic societies. The World Health Organization considers diabetes as a major health challenge “When diabetes is uncontrolled, it has dire consequences for health and well-being.” Diabetes, if not well controlled, may cause blindness, kidney failure, lower limb amputation and several other long-term consequences that impact significantly quality of life.
T2DM is an age-related disease. Insulin resistance is the root cause of T2DM, and at the origin of many other diseases.
American Diabetes Association and European Association of Diabetes, aligned with WHO recommend to target insulin resistance, the root cause of T2DM.
Promising medical value of THAC drug candidates
THAC has the ambition to develop a range of game changer drug candidates, on top of first line treatments for Type 2 Diabetes Mellitus (T2DM) patients in order to modify the progression of the disease in response to unmet medical needs as claimed by Agencies.
♦ Therapeutic progress in T2DM has been achieved with several main classes of products, usually prescribed in mono- bi- and tri-therapies, and based on different modes of action for controlling glycemia. Nevertheless, T2DM has still an ineluctable evolution in most patients to insulin requirement, premature death in a context of a decreased expectancy life.
♦ THAC drug candidates are expected to be prescribed on top of first line T2DM treatment, by sub-cutaneous and oral administration.
♦ THAC invests in R&D and has a strong preclinical and clinical study program ongoing and planned.
♦ Several family patents ave already been granted to protect THAC drug candidates in different diseases and territories. Other patents are pending.
♦ ALF-5755 unique and innovative mechanism of action and the scientific and clinical results already observed are the object of publications in high level scientific journals.
♦ THAC assets are based on the discoveries by Prof. C. Bréchot et al. at INSERM in the 1990’s and further studied.
Insulin resistance, the root cause of T2DM
Aging is a natural process characterized by many cellular and molecular changes including inflammation and oxidative stress. Though physiological, these asymptomatic changes eventually lead to the development of insulin-resistance, a major risk factor for age-related diseases. Amongst them, T2DM and its complications.
Inactivity, overnutrition and to a lesser extent genetics are to add to aging as the main drivers for inflammation and oxidative stress (through the production of reactive oxygen species-ROS). These latter lead to insulin resistance which is responsible to the blood glucose increase, enhancing hyperglycaemia and hyperinsulinemia.
Insulin resistance starts early in life, is silent and asymptomatic for many years, may lead to severe complications and can cause premature death.
Insulin resistance is common to many age-related diseases such as cancer, liver diseases, dyslipidemia, diabetes and prediabetes, Alzheimer’s disease, polycystic ovary syndrome and cardiovascular diseases.
The binding of insulin on tis receptor activates the receptor of glucose ….
…. Which allows the capture of the blood glucose by the cells..
